trending Market Intelligence /marketintelligence/en/news-insights/trending/RG-pP5PuntBHJBAXs7Tzfw2 content esgSubNav
In This List

Arbutus Biopharma regains Nasdaq compliance

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Arbutus Biopharma regains Nasdaq compliance

Arbutus Biopharma Corp. regained compliance with the Nasdaq Stock Market's listing standards after appointing Daniel Burgess as a director and the third member of its audit committee.

The company received a notice of noncompliance after Frank Karbe resigned from the board's audit committee, leaving the audit committee one member short of Nasdaq's listing requirements.